Fresh analysis suggests that people who stop using new weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end traditional diet and exercise regimens.
Published data in a major medical journal points out that while overweight people frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users using these treatments must be aware of the potential of fast rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
That rate of regain suggests a return to starting weight in about one and a half years.
Analyzing Therapies
The analysis, which looked at dozens of studies involving thousands of patients, compared the results of these new drugs with older methods.
Researchers emphasize that people who shed pounds through lifestyle changes alone typically see a less rapid weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Quick Regain
Doctors believe the mechanism of the jabs accounts for the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making binge eating much more probable."
An Ongoing Disease?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
A number of clinicians contend that, due to the significant potential of relapse, the treatment is often ongoing.
This perspective is echoed by drug manufacturers, who note that the results "highlight the chronic character of excess weight," similar to managing conditions like hypertension.
Patient Experiences
Users who have discontinued the medication describe a powerful resurgence of cravings.
"I experienced a trigger flipping and I was suddenly starving," said a patient.
This challenge is compounded if users have not established lasting dietary or behavioural changes during treatment.
Significant Interest
Figures indicate that millions of adults in the UK have used these injections in the last 12 months, with interest being substantial.
- Adoption is greater among females than men.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while these medications are potent tools for shedding pounds, they are not a permanent cure and long-term success likely depends on combined behavioural support.
